Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Researchers Highlight Risks of RHC in Pediatric Patients With PAH

May 16th 2022, 6:46pm


Based on their findings, the researchers of the retrospective study are calling for close evaluation, careful monitoring, and appropriate treatment to mitigate complications and mortality.

Novel Therapies Targeting Vasoconstriction and Vascular Remodeling May Improve Outcomes in PAH

May 8th 2022, 11:22am


Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.

Dr Gary Owens on the Future of PAH Research

May 2nd 2022, 2:56pm


Gary Owens, MD, president of Gary Owens Associates, discusses current treatments available for pulmonary arterial hypertension (PAH) and where future directions in research may lead.

Review: Investigational Therapies Could Transform PAH Treatment

April 28th 2022, 10:36am


A new commentary suggests new pathways might lead to a major shift in the treatment of pulmonary arterial hypertension (PAH).

Dr Gary Owens Explains Opportunities to More Efficiently Identify, Diagnose PAH

April 25th 2022, 6:01pm


Gary Owens, MD, president of Gary Owens Associates, outlines the current epidemiological knowledge of pulmonary arterial hypertension (PAH).

Review Says Therapies Are Boosting Survival From PAH

April 21st 2022, 7:37pm


A new review article shows positive trends in survival, as scientists better understand the different types and symptoms of pulmonary arterial hypertension (PAH).

Dapagliflozin Combo Is Not More Effective in Reducing PAH in Preclinical Study

April 16th 2022, 11:42am


The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.

Mental Disorders Common in Patients With CTEPH

April 5th 2022, 7:33pm


Panic disorders and specific phobias were the mental disorders most often seen among individuals who have chronic thromboembolic pulmonary hypertension (CTEPH), according to new research.

Enhancing Hemodynamic Parameters in Acute Decompensated Right Heart Failure in Patients With CTD-PAH

March 31st 2022, 2:07pm


Levosimendan appeared to increase in-hospital survival rates, although no long-term survival benefit was reported, among patients with comorbid heart failure and connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH).

Age, Gender Impact Survival With IPAH, Finds South Korean Study

March 25th 2022, 2:50pm


Drawing on over a decade’s worth of data, new research shows that the 10-year survival of over 9000 patients with idiopathic pulmonary arterial hypertension (IPAH) was 57%.